8-K: Acasti Pharma's Phase 3 Trial Reaches 50% Enrollment Milestone, NDA Submission Expected in 2025

Acasti Pharma announced that its pivotal Phase 3 STRIVE-ON safety trial for GTX-104 has exceeded the 50% enrollment milestone, with completion of patient enrollment anticipated in late 2024 to early 2025.

Summary

• Acasti Pharma has achieved a significant milestone with its Phase 3 STRIVE-ON safety trial, surpassing 50% enrollment.
• The STRIVE-ON trial is evaluating GTX-104, an intravenous formulation of nimodipine, against oral nimodipine for treating aneurysmal subarachnoid hemorrhage (aSAH).
• The trial is a randomized, open-label study with a 1:1 ratio, involving 100 patients hospitalized for aSAH.
• Patient enrollment began in October 2023, and the company anticipates completing enrollment between late 2024 and early 2025.
• Acasti is targeting a potential New Drug Application (NDA) submission to the FDA in the first half of calendar year 2025.
• The primary endpoint of the trial is safety, measured by comparing adverse events, including hypotension, between the two treatment groups.
• The addressable market for GTX-104 in the United States is estimated to be around $300 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the achievement of a key milestone in the clinical trial, the clear timeline for future steps, and the potential market opportunity. The language used is optimistic and forward-looking.

Positives

• The achievement of the 50% enrollment milestone demonstrates strong progress in the STRIVE-ON trial.
• The anticipated completion of enrollment in late 2024 to early 2025 keeps the trial on schedule.
• The potential NDA submission in the first half of 2025 indicates a clear path towards regulatory approval.
• GTX-104 offers a potential intravenous alternative to oral nimodipine, addressing challenges in administering medication to aSAH patients.
• The estimated $300 million addressable market in the US suggests significant commercial potential for GTX-104.
• GTX-104 has shown good tolerability and lower pharmacokinetic variability in previous studies.

Risks

• The success and timing of regulatory submissions for GTX-104 are subject to uncertainty.
• Changes to clinical trial designs and regulatory pathways could impact the timeline.
• Legislative, regulatory, political, and economic developments could affect the trial and approval process.
• Actual costs associated with the clinical trials may differ from current expectations.

Future Outlook

Acasti anticipates completing patient enrollment in the STRIVE-ON trial in late 2024 to early 2025 and is targeting a potential NDA submission to the FDA in the first half of calendar 2025.

Management Comments

• Prashant Kohli, CEO of Acasti, stated that the 50% enrollment milestone reflects a laser-sharp focus from both participating clinical trial sites and the Acasti team.
• Dr. Abhishek Ray, Associate Professor of Neurological Surgery, believes GTX-104 shows great promise as an IV alternative to oral nimodipine.

Industry Context

This announcement is significant in the context of rare disease drug development, as it highlights progress in a Phase 3 trial for a novel treatment for aSAH, a condition with high unmet medical needs. The development of an intravenous alternative to oral nimodipine could address significant challenges in patient care.

Comparison to Industry Standards

• The STRIVE-ON trial is a Phase 3 study, which is a standard step in the drug development process, similar to other pharmaceutical companies developing new treatments.
• The use of a randomized, open-label, parallel group design is a common approach in clinical trials, ensuring a robust comparison between the investigational drug and the standard of care.
• The target of 100 patients is a reasonable sample size for a Phase 3 trial in a rare disease, similar to other trials in this space.
• The estimated $300 million addressable market in the US is a typical market size for a rare disease treatment, comparable to other orphan drug opportunities.

Stakeholder Impact

• Shareholders will likely view the progress in the Phase 3 trial positively.
• Patients with aSAH and their families may benefit from the potential availability of a new treatment option.
• Healthcare providers may have a new tool for managing aSAH patients.
• Employees of Acasti Pharma will be involved in the continued development and commercialization of GTX-104.

Next Steps

• Complete patient enrollment in the STRIVE-ON trial.
• Analyze the data from the STRIVE-ON trial.
• Prepare and submit a New Drug Application (NDA) to the FDA.

Key Dates

Keywords

Acasti Pharma, GTX-104, Nimodipine, aSAH, Subarachnoid Hemorrhage, Phase 3 Trial, Clinical Trial, NDA Submission, Orphan Drug, Intravenous, Neurology